The European Medicines Agency (EMA) published on 6 May 2026 the minutes of its Pharmacovigilance Risk Assessment Committee (PRAC) meeting held from 9 to 12 March 2026. The document outlines safety assessments, signal evaluations, and recommendations for several medicinal products, impacting pharmaceutical companies, healthcare professionals, and patients across the EU.
The minutes, released by EMA's PRAC, detail the committee's review of emerging safety data and proposed regulatory actions. Key topics included the evaluation of new signals for potential adverse drug reactions, updates to product information, and the initiation of referrals for certain medicines. The document serves as a formal record of the committee's discussions and decisions, which are non-binding but typically guide national competent authorities.
Policy orientations and trade-offs PRAC's work involves balancing patient safety with continued access to medicines. For instance, when a safety signal is confirmed, the committee may recommend updating the product's summary of product characteristics (SmPC) or package leaflet, adding warnings or contraindications. This can reduce risks but may also limit the medicine's use or require additional monitoring. In some cases, PRAC may recommend suspending or revoking a marketing authorisation if risks outweigh benefits, a decision that carries significant economic implications for the manufacturer and may reduce treatment options for patients.
Impact on stakeholders Pharmaceutical companies face potential costs from implementing label changes, conducting additional studies, or managing market withdrawals. Healthcare professionals must adapt prescribing practices based on updated safety information. Patients may benefit from reduced risks but could lose access to certain therapies. EU regulatory bodies, including national agencies, are expected to follow up on PRAC recommendations, ensuring consistent implementation across member states.
Expected institutional follow-up EMA will publish any resulting regulatory actions, such as updated product information or referral outcomes, in subsequent communications. The next PRAC meeting is scheduled for April 2026, where further signals and ongoing reviews will be addressed.
← Atlas › News › Health & Lifestyle